Tweet
Maxim Group reissued their buy rating on shares of Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) in a research note published on Tuesday. The brokerage currently has a $3.00 price objective on the biotechnology company's stock.
"Actinium announced that the Data Monitoring Committee (DMC) unanimously voted to recommend the Phase 3 SIERRA trial of Iomab-B to continue as planned. The interim safety look occurred at the 25% enrollment mark. The company will host a conference call Wednesday/tomorrow at 9am ET."," the firm's analyst commented. Get Actinium Pharmaceuticals alerts:
Several other research firms also recently commented on ATNM. Zacks Investment Research downgraded Actinium Pharmaceuticals from a hold rating to a sell rating in a report on Tuesday, June 5th. B. Riley boosted their price target on Actinium Pharmaceuticals from $2.75 to $3.00 and gave the company a buy rating in a report on Thursday, July 12th. Five investment analysts have rated the stock with a buy rating, The stock presently has an average rating of Buy and a consensus price target of $3.75.
Shares of NYSEAMERICAN ATNM opened at $0.64 on Tuesday. Actinium Pharmaceuticals has a 1-year low of $0.33 and a 1-year high of $0.85.
Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last posted its quarterly earnings results on Thursday, August 9th. The biotechnology company reported ($0.04) EPS for the quarter, topping the Zacks' consensus estimate of ($0.06) by $0.02.
A number of large investors have recently made changes to their positions in the stock. Renaissance Technologies LLC increased its holdings in Actinium Pharmaceuticals by 1,269.5% during the 2nd quarter. Renaissance Technologies LLC now owns 387,500 shares of the biotechnology company's stock valued at $248,000 after purchasing an additional 359,205 shares during the period. Worth Venture Partners LLC purchased a new position in Actinium Pharmaceuticals during the 1st quarter valued at about $140,000. Sio Capital Management LLC purchased a new position in Actinium Pharmaceuticals during the 1st quarter valued at about $393,000. Sabby Management LLC bought a new stake in Actinium Pharmaceuticals during the 1st quarter valued at approximately $729,000. Finally, Anson Funds Management LP bought a new stake in Actinium Pharmaceuticals during the 1st quarter valued at approximately $1,502,000.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for patients with cancers lacking effective treatment options. Its lead product candidate is Iomab-B that is in Phase III clinical studies for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older.
Recommended Story: Technical Analysis Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter 